Recent Finacing
Recent Raise
Imara is a Cambridge, MA-based clinical-stage biopharmaceutical company developing IMR-687, an orally administered selective PDE9 inhibitor for sickle cell disease and other hemoglobinopathies, currently in Phase 2a.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Imara.
